Clinical trial
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With…
NCT00001962 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Terminated
Key facts
| NCT number | NCT00001962 |
|---|---|
| Title | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure |
| Official title | A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 100 |
| Start date | Nov 1, 1999 |
| Primary completion | Aug 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Jan 19, 2000 |
| Last update posted | Jul 9, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: